day one biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. we are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. we are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.
Company profile
Ticker
DAWN
Exchange
Website
CEO
Jeremy Bender
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Day One Biopharmaceuticals Holding Co LLC
SEC CIK
Corporate docs
IRS number
832415215
DAWN stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
24 Apr 24
ARS
2023 FY
Annual report to shareholders
5 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
8-K
Other Events
7 Mar 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
26 Feb 24
8-K
Day One Announces Two New Appointments to Board of Directors
17 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
S-8
Registration of securities for employees
4 Jan 24
Latest ownership filings
4
Samuel C. Blackman
22 Apr 24
4
Samuel C. Blackman
26 Mar 24
4
Samuel C. Blackman
13 Mar 24
4
Samuel C. Blackman
28 Feb 24
144
Notice of proposed sale of securities
27 Feb 24
4
Adam Dubow
20 Feb 24
4
Charles N York II
20 Feb 24
4
Samuel C. Blackman
20 Feb 24
4
Jeremy Bender
20 Feb 24
144
Notice of proposed sale of securities
16 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 241.18 mm | 241.18 mm | 241.18 mm | 241.18 mm | 241.18 mm | 241.18 mm |
Cash burn (monthly) | (no burn) | (no burn) | 17.15 mm | 15.77 mm | 12.35 mm | 11.73 mm |
Cash used (since last report) | n/a | n/a | 117.66 mm | 108.25 mm | 84.78 mm | 80.51 mm |
Cash remaining | n/a | n/a | 123.52 mm | 132.93 mm | 156.40 mm | 160.67 mm |
Runway (months of cash) | n/a | n/a | 7.2 | 8.4 | 12.7 | 13.7 |
Institutional ownership, Q3 2022
94.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 95 |
Opened positions | 23 |
Closed positions | 21 |
Increased positions | 35 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 1.57 bn |
Total shares | 82.38 mm |
Total puts | 24.60 k |
Total calls | 71.70 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
AI Day 1 | 10.68 mm | $168.71 mm |
FMR | 8.79 mm | $176.09 mm |
Atlas Venture Life Science Advisors | 8.17 mm | $163.63 mm |
Ra Capital Management | 7.04 mm | $141.02 mm |
Canaan XI | 6.96 mm | $127.45 mm |
Canaan Partners XI | 6.96 mm | $139.50 mm |
TAK Takeda Pharmaceutical | 6.01 mm | $101.32 mm |
Adage Capital Partners GP, L.L.C. | 3.04 mm | $60.89 mm |
Vanguard | 2.62 mm | $52.39 mm |
BLK Blackrock | 2.54 mm | $50.90 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | Samuel C. Blackman | Common Stock | Sell | Dispose S | No | Yes | 16.0163 | 10,000 | 160.16 k | 1,174,662 |
25 Mar 24 | Samuel C. Blackman | Common Stock | Sell | Dispose S | No | Yes | 16.0055 | 10,000 | 160.06 k | 1,184,662 |
11 Mar 24 | Samuel C. Blackman | Common Stock | Sell | Dispose S | No | Yes | 15.2438 | 30,000 | 457.31 k | 1,194,662 |
27 Feb 24 | Samuel C. Blackman | Common Stock | Sell | Dispose S | No | Yes | 16.1083 | 20,000 | 322.17 k | 1,224,662 |
16 Feb 24 | Jeremy Bender | Common Stock | Sell | Dispose S | No | No | 15.2481 | 7,615 | 116.11 k | 721,813 |
15 Feb 24 | Jeremy Bender | Common Stock | Option exercise | Acquire M | No | No | 0 | 11,687 | 0.00 | 729,428 |
15 Feb 24 | Jeremy Bender | Common Stock | Option exercise | Acquire M | No | No | 0 | 4,750 | 0.00 | 717,741 |
15 Feb 24 | Jeremy Bender | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,562 | 0.00 | 712,991 |
15 Feb 24 | Jeremy Bender | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 11,687 | 0.00 | 175,313 |
15 Feb 24 | Jeremy Bender | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 4,750 | 0.00 | 52,250 |
News
Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target
25 Apr 24
HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $50 Price Target
24 Apr 24
Needham Maintains Buy on Day One Biopharmaceutical, Raises Price Target to $33
24 Apr 24
Day One's OJEMDA Receives U.S. FDA Accelerated Approval For Relapsed Or Refractory BRAF-Altered Pediatric Low-Grade Glioma
23 Apr 24
JP Morgan Maintains Overweight on Day One Biopharmaceutical, Raises Price Target to $36
22 Apr 24
Press releases
Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
23 Apr 24
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
26 Feb 24